JP2013532660A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532660A5 JP2013532660A5 JP2013520869A JP2013520869A JP2013532660A5 JP 2013532660 A5 JP2013532660 A5 JP 2013532660A5 JP 2013520869 A JP2013520869 A JP 2013520869A JP 2013520869 A JP2013520869 A JP 2013520869A JP 2013532660 A5 JP2013532660 A5 JP 2013532660A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- alkoxy
- optionally substituted
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 100
- 125000003545 alkoxy group Chemical group 0.000 claims 44
- 229910052739 hydrogen Inorganic materials 0.000 claims 40
- 239000001257 hydrogen Substances 0.000 claims 40
- 229910052736 halogen Inorganic materials 0.000 claims 38
- 150000002367 halogens Chemical class 0.000 claims 38
- 125000001424 substituent group Chemical group 0.000 claims 36
- 150000002431 hydrogen Chemical class 0.000 claims 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 28
- 125000003342 alkenyl group Chemical group 0.000 claims 26
- 125000004093 cyano group Chemical group *C#N 0.000 claims 26
- 125000000304 alkynyl group Chemical group 0.000 claims 24
- 125000000623 heterocyclic group Chemical group 0.000 claims 24
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 20
- 229910052757 nitrogen Inorganic materials 0.000 claims 16
- -1 stereoisomers Chemical class 0.000 claims 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 15
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 150000002148 esters Chemical class 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 125000003302 alkenyloxy group Chemical group 0.000 claims 4
- 125000005133 alkynyloxy group Chemical group 0.000 claims 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- DITZKPGGPGEQCE-UHFFFAOYSA-N azulene-5-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=CC=CC2=C1 DITZKPGGPGEQCE-UHFFFAOYSA-N 0.000 claims 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- ZMGWNKLTJQXNAB-UHFFFAOYSA-N 2h-chromene-6-carboxylic acid Chemical compound O1CC=CC2=CC(C(=O)O)=CC=C21 ZMGWNKLTJQXNAB-UHFFFAOYSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- WSVSRNIYZVCNIY-UHFFFAOYSA-N 7-(benzenesulfonylmethyl)-4-methyl-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical compound C1=2C=COC=2C(C)OC(C=2C(O)=O)=C1C=CC=2CS(=O)(=O)C1=CC=CC=C1 WSVSRNIYZVCNIY-UHFFFAOYSA-N 0.000 claims 1
- ZTKSCKSNALMGMI-UHFFFAOYSA-N 7-(benzenesulfonylmethyl)-4-oxofuro[2,3-c]chromene-6-carboxylic acid Chemical compound C1=CC=2C=3C=COC=3C(=O)OC=2C(C(=O)O)=C1CS(=O)(=O)C1=CC=CC=C1 ZTKSCKSNALMGMI-UHFFFAOYSA-N 0.000 claims 1
- YATHIMWFGWBSIT-UHFFFAOYSA-N 7-(benzenesulfonylmethyl)-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical compound C1=CC=2C=3C=COC=3COC=2C(C(=O)O)=C1CS(=O)(=O)C1=CC=CC=C1 YATHIMWFGWBSIT-UHFFFAOYSA-N 0.000 claims 1
- DCYRGSMTVUUKSL-UHFFFAOYSA-N 7-(benzenesulfonylmethyl)furo[2,3-c]quinoline-6-carboxylic acid Chemical compound C1=CC2=C3C=COC3=CN=C2C(C(=O)O)=C1CS(=O)(=O)C1=CC=CC=C1 DCYRGSMTVUUKSL-UHFFFAOYSA-N 0.000 claims 1
- RFPRHKPCTLCDEC-AATRIKPKSA-N 7-[[2-[(e)-3-(diethylamino)prop-1-enyl]-4-fluorophenyl]sulfonylamino]-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical class CCN(CC)C\C=C\C1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C(C2=C(OC=C2)CO2)C2=C1C(O)=O RFPRHKPCTLCDEC-AATRIKPKSA-N 0.000 claims 1
- RFPRHKPCTLCDEC-WAYWQWQTSA-N 7-[[2-[(z)-3-(diethylamino)prop-1-enyl]-4-fluorophenyl]sulfonylamino]-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical compound CCN(CC)C\C=C/C1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C(C2=C(OC=C2)CO2)C2=C1C(O)=O RFPRHKPCTLCDEC-WAYWQWQTSA-N 0.000 claims 1
- CBJSPEGLDIAGBF-ARJAWSKDSA-N 7-[[2-[(z)-3-(ethylamino)prop-1-enyl]-4-fluorophenyl]sulfonylamino]-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical compound CCNC\C=C/C1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C(C2=C(OC=C2)CO2)C2=C1C(O)=O CBJSPEGLDIAGBF-ARJAWSKDSA-N 0.000 claims 1
- CNSPMLOZLHMVQX-UHFFFAOYSA-N 7-[[2-[3-(diethylamino)propyl]-4-fluorophenyl]sulfonylamino]-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical compound CCN(CC)CCCC1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C(C2=C(OC=C2)CO2)C2=C1C(O)=O CNSPMLOZLHMVQX-UHFFFAOYSA-N 0.000 claims 1
- QNLSUCSABPHYKA-UHFFFAOYSA-N 7-[[2-[3-(diethylamino)propyl]-4-fluorophenyl]sulfonylamino]furo[2,3-c]quinoline-6-carboxylic acid Chemical compound CCN(CC)CCCC1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C(C2=C(OC=C2)C=N2)C2=C1C(O)=O QNLSUCSABPHYKA-UHFFFAOYSA-N 0.000 claims 1
- DWXHOVUMTHMVJK-UPHRSURJSA-N 7-[[4-fluoro-2-[(z)-3-(3-hydroxyazetidin-1-yl)prop-1-enyl]phenyl]sulfonylamino]-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical compound C1C(O)CN1C\C=C/C1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C(C2=C(OC=C2)CO2)C2=C1C(O)=O DWXHOVUMTHMVJK-UPHRSURJSA-N 0.000 claims 1
- TVRQUVMDOXDPBM-NLVOMGJBSA-N 7-[[4-fluoro-2-[(z)-3-[(3r)-3-hydroxypyrrolidin-1-yl]prop-1-enyl]phenyl]sulfonylamino]-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical compound C1[C@H](O)CCN1C\C=C/C1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C(C2=C(OC=C2)CO2)C2=C1C(O)=O TVRQUVMDOXDPBM-NLVOMGJBSA-N 0.000 claims 1
- TVRQUVMDOXDPBM-YYZONTRBSA-N 7-[[4-fluoro-2-[(z)-3-[(3s)-3-hydroxypyrrolidin-1-yl]prop-1-enyl]phenyl]sulfonylamino]-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical compound C1[C@@H](O)CCN1C\C=C/C1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C(C2=C(OC=C2)CO2)C2=C1C(O)=O TVRQUVMDOXDPBM-YYZONTRBSA-N 0.000 claims 1
- ISTCDIQUYWIORV-UPHRSURJSA-N 7-[[4-fluoro-2-[(z)-3-morpholin-4-ylprop-1-enyl]phenyl]sulfonylamino]-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical compound C1=CC=2C=3C=COC=3COC=2C(C(=O)O)=C1NS(=O)(=O)C1=CC=C(F)C=C1\C=C/CN1CCOCC1 ISTCDIQUYWIORV-UPHRSURJSA-N 0.000 claims 1
- WTWWMQFXEKRNCA-ARJAWSKDSA-N 7-[[4-fluoro-2-[(z)-3-pyrrolidin-1-ylprop-1-enyl]phenyl]sulfonylamino]-4h-furo[2,3-c]chromene-6-carboxylic acid Chemical compound C1=CC=2C=3C=COC=3COC=2C(C(=O)O)=C1NS(=O)(=O)C1=CC=C(F)C=C1\C=C/CN1CCCC1 WTWWMQFXEKRNCA-ARJAWSKDSA-N 0.000 claims 1
- BRPFFWNUJBVZEB-UHFFFAOYSA-N 8-(benzenesulfonylmethyl)-4,5-dihydrofuro[2,3-d][1]benzoxepine-7-carboxylic acid Chemical compound C1=CC=2C=3C=COC=3CCOC=2C(C(=O)O)=C1CS(=O)(=O)C1=CC=CC=C1 BRPFFWNUJBVZEB-UHFFFAOYSA-N 0.000 claims 1
- 239000005973 Carvone Substances 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 102000002933 Thioredoxin Human genes 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000003579 anti-obesity Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229940094937 thioredoxin Drugs 0.000 claims 1
- 108060008226 thioredoxin Proteins 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36665010P | 2010-07-22 | 2010-07-22 | |
| US61/366,650 | 2010-07-22 | ||
| US201161470093P | 2011-03-31 | 2011-03-31 | |
| US61/470,093 | 2011-03-31 | ||
| PCT/US2011/044864 WO2012012642A1 (en) | 2010-07-22 | 2011-07-21 | Tricyclic compounds and methds of making and using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013532660A JP2013532660A (ja) | 2013-08-19 |
| JP2013532660A5 true JP2013532660A5 (enExample) | 2014-09-11 |
| JP5913310B2 JP5913310B2 (ja) | 2016-04-27 |
Family
ID=44504203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013520869A Active JP5913310B2 (ja) | 2010-07-22 | 2011-07-21 | 三環式化合物ならびにその作製および使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9266896B2 (enExample) |
| EP (1) | EP2595988B1 (enExample) |
| JP (1) | JP5913310B2 (enExample) |
| KR (1) | KR20130043207A (enExample) |
| CN (1) | CN103249735B (enExample) |
| AU (1) | AU2011281037B2 (enExample) |
| BR (1) | BR112013001613A2 (enExample) |
| CA (1) | CA2806221A1 (enExample) |
| MX (1) | MX2013000836A (enExample) |
| WO (1) | WO2012012642A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010065883A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Method of treating an overweight or obese subject |
| US20120004162A1 (en) | 2008-12-04 | 2012-01-05 | Vath James E | Methods of Treating an Overweight or Obese Subject |
| KR20120083905A (ko) | 2009-10-09 | 2012-07-26 | 자프겐 코포레이션 | 비만의 치료에 사용하기 위한 설폰 화합물 |
| CA2786603C (en) | 2010-01-08 | 2018-02-20 | James E. Vath | Fumagillol type compounds and methods of making and using same |
| WO2011085198A1 (en) | 2010-01-08 | 2011-07-14 | Zafgen Corporation | Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph) |
| WO2011127304A2 (en) | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
| KR20130043207A (ko) | 2010-07-22 | 2013-04-29 | 자프겐 인크. | 트리시클릭 화합물 및 이의 제조 및 사용 방법 |
| JP5913333B2 (ja) | 2010-10-12 | 2016-04-27 | ザフゲン，インコーポレイテッド | スルホンアミド化合物、およびそれを製造し使用する方法 |
| CA2819251A1 (en) | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol |
| CA2825408A1 (en) | 2011-01-26 | 2012-08-02 | Zafgen, Inc. | Tetrazole compounds and methods of making and using same |
| JP5876513B2 (ja) | 2011-03-08 | 2016-03-02 | ザフゲン，インコーポレイテッド | オキサスピロ［２．５］オクタン誘導体および類似体 |
| BR112013028665A2 (pt) | 2011-05-06 | 2016-09-06 | Zafgen Inc | compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos |
| BR112013028666A2 (pt) | 2011-05-06 | 2017-08-08 | Zafgen Inc | compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo |
| KR101979039B1 (ko) * | 2011-05-06 | 2019-05-15 | 자프겐 인크. | 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법 |
| EP2763671A2 (en) | 2011-10-03 | 2014-08-13 | Zafgen, Inc. | Methods of treating age related disorders |
| EP2804856B1 (en) * | 2012-01-18 | 2017-03-15 | Zafgen, Inc. | Tricyclic sulfone compounds and methods of making and using same |
| BR112014017673A8 (pt) * | 2012-01-18 | 2017-07-11 | Zafgen Inc | Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos |
| BR112014028041A2 (pt) | 2012-05-08 | 2017-06-27 | Zafgen Inc | tratamento de obesidade hipotalâmica com inibidores de metap2 |
| CA2873574A1 (en) | 2012-05-09 | 2013-11-14 | Zafgen, Inc. | Fumagillol type compounds and methods of making and using same |
| BR112015010225A2 (pt) | 2012-11-05 | 2017-07-11 | Zafgen Inc | compostos tricíclicos e seus métodos de produção e utilização |
| CN104918615B (zh) * | 2012-11-05 | 2018-10-12 | 扎夫根股份有限公司 | 治疗肝病的方法 |
| US9868717B2 (en) | 2012-11-05 | 2018-01-16 | Zafgen, Inc. | Tricyclic sulphonamide compounds and methods of making and using same |
| AU2014236528A1 (en) | 2013-03-14 | 2015-09-24 | Zafgen, Inc. | Methods of treating renal disease and other disorders |
| CN106432255A (zh) | 2015-08-11 | 2017-02-22 | 扎夫根公司 | 烟曲霉素醇螺环化合物和制备和使用其的方法 |
| AR105671A1 (es) | 2015-08-11 | 2017-10-25 | Zafgen Inc | Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso |
| US11066812B2 (en) | 2017-08-07 | 2021-07-20 | Hensley Industries, Inc. | Bucket lip stabilizer structure |
| US10926226B2 (en) * | 2018-03-08 | 2021-02-23 | ExxonMobil Research & Engineering Company Company | Functionalized membranes and methods of production thereof |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4920132A (en) | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| US5164410A (en) | 1988-01-09 | 1992-11-17 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
| PH26256A (en) | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
| US5166172A (en) | 1988-09-01 | 1992-11-24 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
| EP0359036B1 (en) | 1988-09-01 | 1997-03-26 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives |
| US5180738A (en) | 1988-09-01 | 1993-01-19 | Takeda Chemical Industries | Fumagillol derivatives and pharmaceutical compositions thereof |
| US5288722A (en) | 1989-03-06 | 1994-02-22 | Takeda Chemical Industries, Ltd. | 6-amino-6-desoxyfumagillols, production and use thereof |
| EP0387650B1 (en) | 1989-03-06 | 1993-03-31 | Takeda Chemical Industries, Ltd. | 6-epifumagillols, production and use thereof |
| US5290807A (en) | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
| US6017954A (en) | 1989-08-10 | 2000-01-25 | Children's Medical Center Corp. | Method of treating tumors using O-substituted fumagillol derivatives |
| EP0415294A3 (en) | 1989-08-31 | 1991-06-12 | Takeda Chemical Industries, Ltd. | Cyclohexanol derivatives, production and use thereof |
| TW282399B (enExample) | 1990-05-25 | 1996-08-01 | Takeda Pharm Industry Co Ltd | |
| US5238950A (en) | 1991-12-17 | 1993-08-24 | Schering Corporation | Inhibitors of platelet-derived growth factor |
| EP0555693B1 (en) | 1992-01-30 | 2001-09-05 | Takeda Chemical Industries, Ltd. | Method of producing highly watersoluble cyclodextrin complex |
| EP0602586B1 (en) | 1992-12-16 | 1997-06-04 | Takeda Chemical Industries, Ltd. | Stable pharmaceutical composition of fumagillol derivatives |
| AP646A (en) | 1995-03-27 | 1998-04-27 | Sanofi Synthelabo | Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. |
| BR9606546A (pt) | 1995-08-02 | 1998-07-14 | Uriach & Cia Sa J | Novas carboxamidas com atividade fungicida |
| CA2234401A1 (en) | 1995-10-11 | 1997-04-17 | Fujisawa Pharmaceutical Co., Ltd. | Vascular permeation inhibitor |
| EP0799616A1 (en) | 1996-04-01 | 1997-10-08 | Takeda Chemical Industries, Ltd. | Oral composition comprising a fumagillol derivative |
| WO1998005293A2 (en) | 1996-08-02 | 1998-02-12 | The Children's Medical Center Corporation | Method of regulating the female reproductive system through angiogenesis inhibitors |
| US6281245B1 (en) | 1996-10-28 | 2001-08-28 | Versicor, Inc. | Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof |
| US7115632B1 (en) | 1999-05-12 | 2006-10-03 | G. D. Searle & Co. | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
| DE69819878T2 (de) | 1997-03-04 | 2004-04-22 | Monsanto Co. | Divalente sulfonyl-aryl-oder heteroaryl hydroxamsäureverbindungen |
| US6207704B1 (en) | 1997-06-09 | 2001-03-27 | Massachusetts Institute Of Technology | Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof |
| EP1024801B1 (en) | 1997-10-31 | 2004-06-23 | Children's Medical Center Corporation | Method for regulating size and growth of vascularized normal tissue |
| CA2300197A1 (en) | 1997-12-23 | 1999-07-01 | Warner-Lambert Company | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis |
| US6242494B1 (en) | 1998-05-01 | 2001-06-05 | Abbott Laboratories | Substituted β-amino acid inhibitors of methionine aminopeptidase-2 |
| KR100357541B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 5-데메톡시 푸마질롤 유도체 및 그 제조방법 |
| KR100357542B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 푸마질롤 유도체 및 그 제조방법 |
| JP2000116337A (ja) | 1998-10-09 | 2000-04-25 | Nippon Shokuhin Kako Co Ltd | ペットフード |
| US6392099B1 (en) | 1998-11-19 | 2002-05-21 | Eagleview Technologies, Inc. | Method and apparatus for the preparation of ketones |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| IL145923A0 (en) | 1999-04-28 | 2002-07-25 | Aventis Pharma Gmbh | Tri-aryl acid derivatives as ppar receptor ligands |
| EP1223932A4 (en) * | 1999-10-01 | 2003-01-15 | Smithkline Beecham Corp | COMPOUNDS AND METHODS |
| US20020002152A1 (en) | 2000-04-14 | 2002-01-03 | Craig Richard A. | Hydrazide and alkoxyamide angiogenesis inhibitors |
| US6323228B1 (en) | 2000-09-15 | 2001-11-27 | Abbott Laboratories | 3-substituted indole angiogenesis inhibitors |
| AR030631A1 (es) | 2000-09-29 | 2003-08-27 | Abbott Lab | Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis |
| US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| US7084108B2 (en) | 2000-11-01 | 2006-08-01 | Praecis Pharmaceuticals, Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| AU2002246726B2 (en) * | 2000-12-20 | 2007-03-01 | Bristol-Myers Squibb Company | Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists |
| PT1354884E (pt) * | 2000-12-28 | 2007-12-24 | Ono Pharmaceutical Co | Composto de ciclopenta (d) pirazolo [1,5-a] piramida como antagonista de receptor de crf |
| WO2002078699A1 (en) | 2001-03-29 | 2002-10-10 | Smithkline Beecham Corporation | Compounds and methods |
| US6545185B1 (en) | 2001-03-29 | 2003-04-08 | Eagleview Technologies, Inc. | Preparation of ketones from aldehydes |
| US20020183242A1 (en) | 2001-04-11 | 2002-12-05 | Jack Henkin | Peptide antiangiogenic drugs |
| US7087768B2 (en) | 2001-09-27 | 2006-08-08 | Equispharm Co., Ltd. | Fumagillol derivatives and preparing method thereof |
| US6803382B2 (en) | 2001-11-09 | 2004-10-12 | Galderma Research & Development, S.N.C. | Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof |
| US7119120B2 (en) | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
| KR100451485B1 (ko) | 2002-03-28 | 2004-10-06 | 주식회사종근당 | 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물 |
| US6989392B2 (en) | 2002-06-18 | 2006-01-24 | Abbott Laboratories | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists |
| US7030262B2 (en) | 2002-08-06 | 2006-04-18 | Abbott Laboratories | 3-Amino-2-hydroxyalkanoic acids and their prodrugs |
| US20040067266A1 (en) | 2002-10-07 | 2004-04-08 | Toppo Frank R. | Weight loss compound |
| US20040157836A1 (en) | 2002-10-08 | 2004-08-12 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
| US20040068012A1 (en) | 2002-10-08 | 2004-04-08 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
| US7491718B2 (en) | 2002-10-08 | 2009-02-17 | Abbott Laboratories | Sulfonamides having antiangiogenic and anticancer activity |
| US20040204472A1 (en) | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
| US7138412B2 (en) | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
| CA2534887A1 (en) | 2003-08-08 | 2005-02-24 | Janssen Pharmaceutica, N.V. | Process for the preparation of 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds |
| TW200530157A (en) | 2003-09-09 | 2005-09-16 | Japan Tobacco Inc | Dipeptidyl peptidase iv inhibitor |
| WO2005063767A2 (en) | 2003-12-22 | 2005-07-14 | Memory Pharmaceuticals Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof |
| CA2550873A1 (en) | 2003-12-29 | 2005-07-21 | Praecis Pharmaceuticals, Inc. | Inhibitors of methionine aminopeptidase-2 and uses thereof |
| KR100552043B1 (ko) | 2004-02-28 | 2006-02-20 | 주식회사종근당 | 푸마질롤 유도체를 포함하는 비만치료용 조성물 |
| EP1748989A2 (en) | 2004-05-12 | 2007-02-07 | ChemoCentryx Inc | Aryl sulfonamides |
| EP1758880A1 (en) | 2004-06-14 | 2007-03-07 | F.Hoffmann-La Roche Ag | Hydroxamates, their manufacture and use as pharmaceutical agents |
| US20050288516A1 (en) | 2004-06-28 | 2005-12-29 | Warren Jack S | Use of a device or devices, such as a convergent divergent funnel mixer, to optimize the available reaction volume, the raw material feed ratios and the weight hourly space velocity in a tube reactor |
| WO2006004803A1 (en) | 2004-06-30 | 2006-01-12 | Combinatorx, Incorporated | Methods and reagents for the treatment of metabolic disorders |
| US20060019967A1 (en) | 2004-07-21 | 2006-01-26 | Su-Ying Wu | SARS CoV main protease inhibitors |
| US20060045865A1 (en) | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
| WO2006036670A1 (en) | 2004-09-24 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Sulfonamide compounds |
| GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| CA2585383A1 (en) | 2004-10-29 | 2006-05-11 | Gerald W. Shipps, Jr. | Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents |
| EP1841761A4 (en) | 2005-01-26 | 2008-10-29 | Chong Kun Dang Pharm Corp | Fumagillol derivatives or processes for the preparation of fumagillol derivatives, and pharmaceutical compositions containing them |
| FR2886855B1 (fr) | 2005-06-08 | 2009-07-17 | Agronomique Inst Nat Rech | Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques |
| WO2006138475A2 (en) | 2005-06-16 | 2006-12-28 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
| KR20080083680A (ko) | 2005-12-23 | 2008-09-18 | 스미스클라인 비참 코포레이션 | 오로라 키나제의 아자인돌 억제제 |
| EP1976495A2 (en) | 2006-01-06 | 2008-10-08 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| US20080058395A1 (en) | 2006-06-30 | 2008-03-06 | Sepracor Inc. | Fused heterocyclic inhibitors of D-amino acid oxidase |
| WO2008008374A2 (en) | 2006-07-14 | 2008-01-17 | Chemocentryx, Inc. | Ccr2 inhibitors and methods of use thereof |
| DE102007020492A1 (de) | 2007-04-30 | 2008-11-06 | Grünenthal GmbH | Substituierte Sulfonamid-Derivate |
| EP2170402B1 (en) | 2007-06-26 | 2015-03-25 | Children's Medical Center Corporation | Metap-2 inhibitor polymersomes for therapeutic administration |
| US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| EA020251B1 (ru) | 2007-11-28 | 2014-09-30 | Мерсана Терапьютикс, Инк. | Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина |
| CN101932577B (zh) | 2007-11-30 | 2013-07-17 | 拜耳知识产权有限责任公司 | 杂芳基取代的哌啶 |
| CA2731020A1 (en) | 2008-07-18 | 2010-01-21 | Zafgen, Inc. | Use of antiangiogenic fumagillins in the treatment of obesity |
| EP2350012B1 (en) | 2008-10-06 | 2017-06-28 | The Johns Hopkins University | Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders |
| WO2010048499A1 (en) | 2008-10-24 | 2010-04-29 | Wake Forest University | Platinum acridine anti-cancer compounds and methods thereof |
| WO2010065881A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| WO2010065883A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Method of treating an overweight or obese subject |
| US20120010290A1 (en) | 2008-12-04 | 2012-01-12 | Vath James E | Methods of Treating an Overweight or Obese Subject |
| US20120004162A1 (en) | 2008-12-04 | 2012-01-05 | Vath James E | Methods of Treating an Overweight or Obese Subject |
| KR20120083905A (ko) | 2009-10-09 | 2012-07-26 | 자프겐 코포레이션 | 비만의 치료에 사용하기 위한 설폰 화합물 |
| WO2011085198A1 (en) | 2010-01-08 | 2011-07-14 | Zafgen Corporation | Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph) |
| US20130023513A1 (en) | 2010-01-12 | 2013-01-24 | Hughes Thomas E | Methods and Compositions for Treating Cardiovascular Disorders |
| WO2011127304A2 (en) | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
| WO2011150338A1 (en) | 2010-05-27 | 2011-12-01 | Zafgen Corporation | Methods of treating obesity |
| KR20130043207A (ko) | 2010-07-22 | 2013-04-29 | 자프겐 인크. | 트리시클릭 화합물 및 이의 제조 및 사용 방법 |
| JP5913333B2 (ja) | 2010-10-12 | 2016-04-27 | ザフゲン，インコーポレイテッド | スルホンアミド化合物、およびそれを製造し使用する方法 |
| PH12013500934A1 (en) | 2010-11-09 | 2022-10-24 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
| US20140073691A1 (en) | 2010-11-10 | 2014-03-13 | Zafgen, Inc. | Methods and composition for Treating Thyroid Hormone Related Disorders |
| CA2819251A1 (en) | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol |
| WO2012074968A1 (en) | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors |
| US20140011870A1 (en) | 2010-11-29 | 2014-01-09 | Zafgen, Inc. | Methods of Treating Obesity Using an Effective Dose of a METAP-2 Inhibitor |
| CA2825408A1 (en) | 2011-01-26 | 2012-08-02 | Zafgen, Inc. | Tetrazole compounds and methods of making and using same |
| BR112013028665A2 (pt) | 2011-05-06 | 2016-09-06 | Zafgen Inc | compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos |
| BR112013028666A2 (pt) | 2011-05-06 | 2017-08-08 | Zafgen Inc | compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo |
| KR101979039B1 (ko) | 2011-05-06 | 2019-05-15 | 자프겐 인크. | 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법 |
| US9090640B2 (en) | 2011-09-02 | 2015-07-28 | Ulrich Bierbach | Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof |
-
2011
- 2011-07-21 KR KR1020137004371A patent/KR20130043207A/ko not_active Withdrawn
- 2011-07-21 CN CN201180045319.0A patent/CN103249735B/zh not_active Expired - Fee Related
- 2011-07-21 US US13/811,453 patent/US9266896B2/en not_active Expired - Fee Related
- 2011-07-21 CA CA2806221A patent/CA2806221A1/en not_active Abandoned
- 2011-07-21 EP EP11741370.8A patent/EP2595988B1/en active Active
- 2011-07-21 AU AU2011281037A patent/AU2011281037B2/en not_active Ceased
- 2011-07-21 JP JP2013520869A patent/JP5913310B2/ja active Active
- 2011-07-21 MX MX2013000836A patent/MX2013000836A/es active IP Right Grant
- 2011-07-21 BR BR112013001613A patent/BR112013001613A2/pt not_active IP Right Cessation
- 2011-07-21 WO PCT/US2011/044864 patent/WO2012012642A1/en not_active Ceased
-
2016
- 2016-01-07 US US14/990,299 patent/US9839623B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013532660A5 (enExample) | ||
| JP2015504091A5 (enExample) | ||
| JP2014513139A5 (enExample) | ||
| JP2016513137A5 (enExample) | ||
| JP2007505933A5 (enExample) | ||
| JP2014513140A5 (enExample) | ||
| JP2011522866A5 (enExample) | ||
| NZ605528A (en) | Ip receptor agonist heterocyclic compounds | |
| HRP20180202T1 (hr) | Purinski derivati, namijenjeni upotrebi u liječenju alergijskih, upalnih i zaraznih bolesti | |
| JP2019512535A5 (enExample) | ||
| TN2016000090A1 (en) | Substituted quinolizine derivatives useful as hiv integrase inhibitors. | |
| WO2009005674A3 (en) | Novel hiv reverse transcriptase inhibitors | |
| MX2015010741A (es) | Derivado de tetrahidroimidazo[1,5-d] [1,4]oxazepina. | |
| JP2014037426A5 (enExample) | ||
| JP2013539789A5 (enExample) | ||
| JP2016521276A5 (enExample) | ||
| EA201100763A1 (ru) | Методы получения хинолиновых производных | |
| WO2016097869A4 (en) | Fused ring heteroaryl compounds and their use as trk inhibitors | |
| JP2016503797A5 (enExample) | ||
| RU2013141274A (ru) | Содержащие фосфор соединения в качестве ингибиторов протеинкиназ | |
| WO2009155527A3 (en) | Phosphatidylinositol 3 kinase inhibitors | |
| MX2010007746A (es) | Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de diana de rapamicina de mamifero quinasa y fosfatidilinositol quinasa y su sintesis. | |
| PH12012501800A1 (en) | 2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor | |
| WO2009013348A3 (en) | Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions | |
| WO2008125600A3 (en) | Pyrazole derivatives as p2x7 modulators |